AstraZeneca PLC (AZN)vsReWalk Robotics Ltd (LFWD)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
LFWD
ReWalk Robotics Ltd
$7.12
-0.14%
HEALTHCARE · Cap: $20.11M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 281112% more annual revenue ($61.37B vs $21.82M). AZN leads profitability with a 17.0% profit margin vs -141.3%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
LFWD
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for LFWD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
15.7% revenue growth
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -209.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : LFWD
The strongest argument for LFWD centers on Price/Book, Revenue Growth. Revenue growth of 15.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : LFWD
The primary concerns for LFWD are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while LFWD is a growth play — different risk/reward profiles.
LFWD carries more volatility with a beta of 0.39 — expect wider price swings.
LFWD is growing revenue faster at 15.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 34/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
ReWalk Robotics Ltd
HEALTHCARE · MEDICAL DEVICES · USA
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company is headquartered in Yokneam Illit, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?